. Author manuscript; available in PMC: 2023 Jan 29.

Published in final edited form as: Tuberculosis (Edinb). 2022 Aug 8;136:102246. doi: 10.1016/j.tube.2022.102246

Table 4.

Comparison of Pharmacokinetic Exposures Explained by mg/kg Dosage and Predicted NAT2 Acetylation Phenotype.

Site	Slope	P value, ANCOVA Dosage*phenotype

C_max, μg/mL per mg/kg change
Overall	0.67
Slow-Intermediate	0.73	0.018
Rapid	0.32
AUC_0–12, h*μg/mL per mg/kg change
Overall	5.0
Slow-Intermediate	5.4	0.003
Rapid	2.5